Valerie C. Mann
Valerie C. Mann
Partner at Lawson Lundell LLP
(604) 631-9173
(604) 641-2811
925 West Georgia St, Suite 1600, Cathedral Pl, Vancouver, BC
Year called to bar: 1992 (BC)
Valerie is the Co-Chair of the Lawson Lundell’s Mergers & Acquisitions Group and Chair of the firm's Technology Group. Her practice is transactional (mergers & acquisitions, corporate finance) as well as advisory. She has been involved in transactions for private and public companies including mergers & acquisitions, financing, and corporate reorganizations as well as strategic alliances and joint ventures. Her practice includes acting for public and private companies as well as for private equity firms and large institutional investors. She has significant experience in private equity and venture fund formations. Val has been lead counsel on a number of large mid-market transactions including in the resource/commodities, real property (acquisitions and joint ventures for the development of industrial and other commercial property), and manufacturing sectors, in addition to acquisition activity in the technology sector. In 2017, Val obtained her ICD.D designation from the Institute of Corporate Directors and the Rotman School of Management. The Best Lawyers in Canada recognizes Val for Corporate Law, Mergers & Acquisitions Law, and Technology Law. Val is called to the British Columbia Bar (1992).
Valerie C. Mann is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Repeatedly Recommended
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Valerie C. Mann is also listed in the following publication(s)
Read more about Valerie C. Mann in ...
On July 26, 2018, Teck Resources Ltd. (Teck) completed the sale of its remaining two-thirds interest in the Waneta Hydroelectric Generating Facility to BC Hydro (BC Hydro) for $1.2B.
On April 12, 2018, Arbutus Biopharma Corporation (Arbutus), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Roivant Sciences Ltd. (Roivant) announced that they have entered into an agreement to launch Genevant Sciences (Genevant), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute US$37.5 million in transaction-related seed capital for Genevant.
On January 12, 2018, Arbutus Biopharma Corp. (Arbutus) closed on a transaction involving the issue and sale of 664,000 series A participating convertible preferred shares of Arbutus (Preferred Shares) to Roivant Sciences Ltd. (Roivant) for gross proceeds to Arbutus of US$66.4 million (Tranche 2).
On July 12, 2016, Ritchie Bros. Auctioneers Inc. (Ritchie Bros.), the world’s largest industrial auctioneer and leading equipment distributor, acquired the remaining 49-per-cent interest that it did not already own in Ritchie Bros. Financial Services Ltd. (RBFS) from a minority shareholder group.
Tekmira Pharmaceuticals Corporation (“Tekmira”) completed a merger of equals with OnCore Biopharma, Inc. (“OnCore”) whereby OnCore merged with a wholly-owned subsidiary of Tekmira. As a result of the merger, stockholders of OnCore hold approximately fifty per cent (50%) of the total number of outstanding shares of capital stock of Tekmira. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, was approximately USD$750 million and at time of closing USD$964 million.